Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 116

Sort by

Sort Order Select

Journal Articles

First-in-human evaluation of IL2RG blockade in patients with severe aplastic anemia that is refractory to or relapsed on immunosuppressive therapy

Blood (2025) 146 (Supplement 1): 27.

https://doi.org/10.1182/blood-2025-27

Published: 2025

Journal Articles

Efficacy and safety of pozelimab plus cemdisiran versus ravulizumab in patients with paroxysmal nocturnal hemoglobinuria who received prior C5 therapy

Jun Ho Jang, Christopher Patriquin, Deepak Taneja, Zhentao Tong, Elham Shirvani Dastgerdi, Amal Souttou, Lorah Perlee, Morag Griffin

Blood (2025) 146 (Supplement 1): 1420.

https://doi.org/10.1182/blood-2025-1420

Published: 2025

Journal Articles

Study design of A phase 3, open-label trial for pozelimab and cemdisiran combination therapy in patients with paroxysmal nocturnal hemoglobinuria with inadequate control of intravascular hemolysis

Blood (2025) 146 (Supplement 1): 4988.

https://doi.org/10.1182/blood-2025-4988

Published: 2025

Journal Articles

Long-term follow-up of patients with aplastic anemia enrolled in two phase 2/3 trials of immunosuppressive therapy plus romiplostim as a first-line treatment: Final report for up to 5 years

Blood (2025) 146 (Supplement 1): 3197.

https://doi.org/10.1182/blood-2025-3197

Published: 2025

Journal Articles

Efficacy and Safety of Pozelimab Plus Cemdisiran Vs Ravulizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria Who Are Naïve to Complement Inhibition

Christopher Patriquin, Jun-Ho Jang, Lisa Aurand, Deepak Taneja, Andrew Magyar, Bradley Dain, Karoline Meagher, Lorah Perlee, Amal Souttou, Morag Griffin

Blood (2024) 144 (Supplement 1): 306.

https://doi.org/10.1182/blood-2024-194610

Published: 2024

Journal Articles

Long-Term Follow-up of Patients with Aplastic Anemia Enrolled in Phase 2/3 Trials of Immunosuppressive Therapy Plus Romiplostim As a First-Line Treatment: Two-Year Interim Analysis

Blood (2024) 144 (Supplement 1): 1310.

https://doi.org/10.1182/blood-2024-193925

Published: 2024

Journal Articles

PHI-101, a Novel FLT3 TKI, Shows Clinical Efficacy in Relapsed/Refractory FLT3-Mutated AML

Blood (2024) 144 (Supplement 1): 1495.

https://doi.org/10.1182/blood-2024-207033

Published: 2024

Journal Articles

The Co-Occurrence of bZIP in-Frame CEBPA -Mutation with Unfavorable Genetic Abnormalities Is Associated with a Poor Prognosis in Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 6035.

https://doi.org/10.1182/blood-2023-180499

Published: 2023

Journal Articles

Trial in Progress: An Open Label Phase I/II, Multicenter Study Evaluating Safety, Pharmacokinetics and Efficacy of S65487, a BCL-2 Inhibitor Combined with Azacitidine in Adults with Previously Untreated Acute Myeloid Leukemia Ineligible for Intensive Treatment

Ana Alfonso Pierola, Stephane De Botton, Jun Ho Jang, Victoria Campbell, Jenny O'Nions, Maria Calbacho, Annette L. Ervin-Haynes, Kristen Keagle, Aline Maillard, Maud Beneton, Mathilde Romagnoli, Alberto Broniscer

Blood (2023) 142 (Supplement 1): 1555.

https://doi.org/10.1182/blood-2023-180795

Published: 2023

Journal Articles

PHI-101 As a Potent Next-Generation FLT3 Inhibitor, Overcome Resistances in Previously Treated Patients with FLT3-ITD or TKD Acute Myeloid Leukemia: Results of a Phase Ia/Ib Clinical Trial

Sung-Soo Yoon, Dongyeop Shin, Je-Hwan Lee, Jun Ho Jang, June-Won Cheong, Ho-Jin Shin, Jeong-Ok Lee, Yoo Jin Lee, Joseph Clarey, Gi-Jun Sung, Kyung-Ah Kim, Ky-Youb Nam, Kyu-Tae Kim, June Han, JeongHyeok Yoon, Bao Nguyen, Li Li, Donald Small

Blood (2023) 142 (Supplement 1): 4283.

https://doi.org/10.1182/blood-2023-185606

Published: 2023

Journal Articles

Red Blood Cell Transfusion Dependence Is Associated with Greater Healthcare Resource Utilization, Higher Medical Cost, and Poorer Prognosis in Patients with Lower-Risk Myelodysplastic Syndromes: A 28-Year Retrospective Observation Study Result

Jun Ho Jang, Ji-Hyun Kim, Kyungah Lee, Eugene Kim, Hyojin Kim, Fangyuan Wang

Blood (2023) 142 (Supplement 1): 1869.

https://doi.org/10.1182/blood-2023-173351

Published: 2023

Journal Articles

Exposure-Response Relationships between the Complement Factor B Inhibitor Iptacopan and Lactate Dehydrogenase (LDH) and Hemoglobin (Hb) in Patients (Pts) with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Antonio M Risitano, Regis Peffault De Latour, Jun Ho Jang, Eng-Soo Yap, Christian Bartels, Guido Junge, Marion Dahlke, Irina Baltcheva

Blood (2023) 142 (Supplement 1): 5643.

https://doi.org/10.1182/blood-2023-179960

Published: 2023

Journal Articles

Efficacy of SB12 (Eculizumab Biosimilar) in Asian and Non-Asian Patients with Paroxysmal Nocturnal Hemoglobinuria: Subgroup Analysis of a Global Phase III Randomized Controlled Trial

Jun Ho Jang, Soo Min Lim, Ciprian Tomuleasa, Hanna Oliynyk, Theerin Lanamtieng, Jihye Park, Younsoo Kim, Jinah Jung, Paola Russo

Blood (2023) 142 (Supplement 1): 2727.

https://doi.org/10.1182/blood-2023-191275

Published: 2023

Journal Articles

A Phase 2, Randomized Trial Evaluating the Safety and Efficacy of Pozelimab and Cemdisiran in Patients with Paroxysmal Nocturnal Hemoglobinuria

Jun Ho Jang, Raymond Wong, Rodrigo Pavani, Lisa Aurand, Bradley Dain, Lorah Perlee, Amal Souttou, Jonathan Weyne, Richard Kelly

Blood (2022) 140 (Supplement 1): 8172–8173.

https://doi.org/10.1182/blood-2022-163236

Published: 2022

Journal Articles

Efficacy and Safety of Long-Term Romiplostim Use for Refractory Aplastic Anemia

Blood (2022) 140 (Supplement 1): 8634–8637.

https://doi.org/10.1182/blood-2022-162895

Published: 2022

Journal Articles

Characterization for the Similarity Assessment between SB12 (Eculizumab Biosimilar) and Eculizumab Using State-of-the-Art Analytical Method

Jun Ho Jang, Eunkyoung Hong, Hyunsoo Kim, Yikwon Kim, Taekyung Yoo, Jungmin Lee

Blood (2022) 140 (Supplement 1): 11049.

https://doi.org/10.1182/blood-2022-166295

Published: 2022

Journal Articles

Long-Term Efficacy and Safety of Pozelimab Monotherapy in Patients with Paroxysmal Nocturnal Hemoglobinuria

Jun Ho Jang, Raymond Wong, Jonathan Weyne, Umesh Chaudhari, Jutta Miller, Bradley Dain, Morag Griffin

Blood (2022) 140 (Supplement 1): 5309–5310.

https://doi.org/10.1182/blood-2022-166627

Published: 2022

Journal Articles

Sensitivity Analysis on the Primary Efficacy Results of SB12 (Eculizumab Biosimilar) Phase III Study in Paroxysmal Nocturnal Hemoglobinuria Patients

Jun Ho Jang, Roberta Demichelis, Larysa Nogaieva, Lily LL Wong, Soo Min Lim, Younsoo Kim, Jihye Park

Blood (2022) 140 (Supplement 1): 8658–8659.

https://doi.org/10.1182/blood-2022-158387

Published: 2022

Journal Articles

Prognostic Predictability of 2022 European Leukemianet (ELN) Risk Stratification in the Real World

Blood (2022) 140 (Supplement 1): 1018–1019.

https://doi.org/10.1182/blood-2022-166182

Published: 2022

Journal Articles

A Potent Small Molecule Inhibitor of FLT3, PHI-101 Overcomes Resistance in Acute Myeloid Leukemia: Efficacy and PK/PD Profile in Phase 1 First in Human Study

Sung-Soo Yoon, Dong-Yeop Shin, Je-Hwan Lee, Jun Ho Jang, June-Won Cheong, Ho-Jin Shin, Jeong-Ok Lee, Yunsuk Choi, Joseph Clarey, Jeejin Im, Suntae Kim, Ky-Youb Nam, Kyu-Tae Kim, June Han, Jeong Hyeok Yoon, Bao Nguyen, Li Li, Donald Small

Blood (2022) 140 (Supplement 1): 3365–3366.

https://doi.org/10.1182/blood-2022-165000

Published: 2022

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

First-in-human evaluation of IL2RG blockade in patients with severe aplastic anemia that is refractory to or relapsed on immunosuppressive therapy

Efficacy and safety of pozelimab plus cemdisiran versus ravulizumab in patients with paroxysmal nocturnal hemoglobinuria who received prior C5 therapy

Study design of A phase 3, open-label trial for pozelimab and cemdisiran combination therapy in patients with paroxysmal nocturnal hemoglobinuria with inadequate control of intravascular hemolysis

Long-term follow-up of patients with aplastic anemia enrolled in two phase 2/3 trials of immunosuppressive therapy plus romiplostim as a first-line treatment: Final report for up to 5 years

Efficacy and Safety of Pozelimab Plus Cemdisiran Vs Ravulizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria Who Are Naïve to Complement Inhibition

Long-Term Follow-up of Patients with Aplastic Anemia Enrolled in Phase 2/3 Trials of Immunosuppressive Therapy Plus Romiplostim As a First-Line Treatment: Two-Year Interim Analysis

PHI-101, a Novel FLT3 TKI, Shows Clinical Efficacy in Relapsed/Refractory FLT3-Mutated AML

The Co-Occurrence of bZIP in-Frame CEBPA -Mutation with Unfavorable Genetic Abnormalities Is Associated with a Poor Prognosis in Acute Myeloid Leukemia

Trial in Progress: An Open Label Phase I/II, Multicenter Study Evaluating Safety, Pharmacokinetics and Efficacy of S65487, a BCL-2 Inhibitor Combined with Azacitidine in Adults with Previously Untreated Acute Myeloid Leukemia Ineligible for Intensive Treatment

PHI-101 As a Potent Next-Generation FLT3 Inhibitor, Overcome Resistances in Previously Treated Patients with FLT3-ITD or TKD Acute Myeloid Leukemia: Results of a Phase Ia/Ib Clinical Trial

Red Blood Cell Transfusion Dependence Is Associated with Greater Healthcare Resource Utilization, Higher Medical Cost, and Poorer Prognosis in Patients with Lower-Risk Myelodysplastic Syndromes: A 28-Year Retrospective Observation Study Result

Exposure-Response Relationships between the Complement Factor B Inhibitor Iptacopan and Lactate Dehydrogenase (LDH) and Hemoglobin (Hb) in Patients (Pts) with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Efficacy of SB12 (Eculizumab Biosimilar) in Asian and Non-Asian Patients with Paroxysmal Nocturnal Hemoglobinuria: Subgroup Analysis of a Global Phase III Randomized Controlled Trial

A Phase 2, Randomized Trial Evaluating the Safety and Efficacy of Pozelimab and Cemdisiran in Patients with Paroxysmal Nocturnal Hemoglobinuria

Efficacy and Safety of Long-Term Romiplostim Use for Refractory Aplastic Anemia

Characterization for the Similarity Assessment between SB12 (Eculizumab Biosimilar) and Eculizumab Using State-of-the-Art Analytical Method

Long-Term Efficacy and Safety of Pozelimab Monotherapy in Patients with Paroxysmal Nocturnal Hemoglobinuria

Sensitivity Analysis on the Primary Efficacy Results of SB12 (Eculizumab Biosimilar) Phase III Study in Paroxysmal Nocturnal Hemoglobinuria Patients

Prognostic Predictability of 2022 European Leukemianet (ELN) Risk Stratification in the Real World

A Potent Small Molecule Inhibitor of FLT3, PHI-101 Overcomes Resistance in Acute Myeloid Leukemia: Efficacy and PK/PD Profile in Phase 1 First in Human Study

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only